首页> 美国卫生研究院文献>BMJ Case Reports >Full Cases: Massive haematuria successfully managed by intravesical ankaferd in a haemodialysis patient complicated with disseminated intravascular coagulation
【2h】

Full Cases: Massive haematuria successfully managed by intravesical ankaferd in a haemodialysis patient complicated with disseminated intravascular coagulation

机译:全案:血液透析患者并发弥散性血管内凝血的膀胱内穿刺成功治疗了大规模血尿

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务,本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文,但由于OA文献来源多样且变更频繁,仍可能出现获取不到、文献不完整或与标题不符等情况,如果获取不到我们将提供退款服务。请知悉。

摘要

Massive haematuria is a life-threatening condition, demanding immediate management of bleeding. The mortality is very high in the case of delayed management of bleeding, especially in elderly patients with concomitant comorbidity. The treatment options of haematuria are wide, and depend on underlying conditions. However, therapeutic choices are limited in the presence of massive and intractable haematuria caused by disseminated intravascular coagulation (DIC). Ankaferd blood stopper (ABS) is a novel, commercially available, haemostatic agent, which has been approved by the Ministry of Health for local use in Turkey. Here, for the first time in the literature, we report a case of diffuse intravesical bleeding stopped by intravesical use of ABS in a 72-year-old man, haemodialysis patient complicated with sepsis and DIC.
机译:大量血尿会危及生命,需要立即处理出血。在延迟处理出血的情况下,死亡率非常高,尤其是在有合并症的老年患者中。血尿的治疗方法多种多样,并取决于潜在的状况。但是,由于弥散性血管内凝血(DIC)引起的大量难治性血尿,治疗选择受到限制。 Ankaferd止血剂(ABS)是一种新型的市售止血剂,已获卫生部批准在土耳其本地使用。在本文中,我们首次报道了一名72岁男性,血液透析患者并发败血症和DIC的膀胱内使用ABS停止弥漫性膀胱内出血的病例。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
代理获取

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号